Drug Profile

CV 7301

Alternative Names: CV-7301; CVSQIV

Latest Information Update: 06 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CureVac
Developer CureVac; GSK
Class Influenza virus vaccines; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase II Influenza virus infections

Most Recent Events

06 Aug 2024 Phase-II clinical trials in Influenza virus infections (Prevention) (IM) (CureVac pipeline, August 2024)
20 Jul 2020 GlaxoSmithKline and CureVac agree to co-develop mRNA based vaccines for Infectious diseases
24 Apr 2020 CV 7301- is available for licensing as of 24 Apr 2020. https://www.curevac.com/

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com